Clinical Trials Logo
  1. Home
  2. Newly Diagnosed Glioblastoma
  3. NCT03619239

Dose-escalation Study to Evaluate the Safety and Tolerability of GX-I7 in Patients With Glioblastoma — GBM  

Newly Diagnosed Glioblastoma Clinical Trial

Official title:
A Phase 1b, Dose-escalation Study to Evaluate the Safety, Tolerability, and the Lymphocyte Increasing Effects of GX-I7 Intramuscular Administration in Patients With Glioblastoma

Clinical Trial Summary

Patients will be enrolled in two stages: - Dose-escalation stage: Approximately 12-24 patients will be enrolled.

Clinical Trial Description

Detailed Description: • Dose-escalation stage : designed as classical 3+3 to determine MTD(Maximum tolerable dose), RP2D(Recommended Phase 2 Dose) and DLT(Dose-limiting toxicity)s to evaluate approximately four dose levels of GX-I7 - pre-determined dose(Level I)~ pre-determined dose(Level IV) ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03619239
Study type Interventional
Source Genexine, Inc.
Contact
Status Completed
Phase Phase 1
Start date June 20, 2018
Completion date September 25, 2020
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03899857 - Pembrolizumab for Newly Diagnosed Glioblastoma Phase 2
Active, not recruiting NCT05163080 - SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE) Phase 2
Recruiting NCT04474353 - Study of Tumor Treating Fields With Hypofractionated Chemoradiotherapy in Newly Diagnosed Glioblastoma Phase 1
Recruiting NCT05235737 - The Assessment of Immune Response in Newly Diagnosed Glioblastoma Patients Treated With Pembrolizumab Phase 4
Recruiting NCT04840069 - Radiotherapy Planning Using Fluciclovine PET in Patients With Newly Diagnosed Glioblastoma Phase 2
Active, not recruiting NCT03400917 - Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Newly Diagnosed Glioblastoma Phase 2
Completed NCT03345095 - A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma Phase 3
Recruiting NCT04478279 - A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT05864534 - Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma Phase 2
Not yet recruiting NCT04967690 - A Dose Escalation Study to Estimate MTD, DLTs and Pharmacokinetics After a Single Intracranial Dose of SI-053 as an add-on to the Current Standard of Care, in Adult Patients With Newly Diagnosed GBM Phase 1
Active, not recruiting NCT04600817 - A Study to Evaluate the Efficacy and Safety of TJ107 in Lympopenic Patients With Newly Diagnosed Glioblastoma Who Completed Standard Concurrent Chemoradiotherapy (CCRT) Phase 2
Active, not recruiting NCT03782415 - Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent Glioblastoma Phase 1/Phase 2
Recruiting NCT04477200 - Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma Phase 1
Withdrawn NCT04065087 - Efficacy and Safety Study of GX-I7 Plus Adjuvant Temozolomide Combination in Patients With Newly Diagnosed Glioblastoma Phase 1/Phase 2
Recruiting NCT05380349 - Personalized Cancer Stem Cell High-Throughput Drug Screening for Glioblastoma Early Phase 1